NSTK · 01.2026Independent supplement reference
NutriStack
Edition 1.0Updated July 13, 2026

Dapagliflozin

Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026

Dapagliflozin is an SGLT2 inhibitor approved for type 2 diabetes, heart failure (with reduced or preserved ejection fraction), and chronic kidney disease. The DAPA-HF and DAPA-CKD trials established its broad cardiorenal benefits, making it one of the first diabetes medications approved for heart failure independent of diabetes status.

Evidence tier
Strong
Indexed sources
10 2023–2025
Interactions
0
Category
Prescription
Read the sources → Compare profiles
Publication status

Exploratory record, not a reviewed medical publication.

See the editorial and medical-review policies for the publication gate.

This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.

In short

What the research says.

A quick, data-only summary. The full evidence, dosing, and sources are below.

Dapagliflozin is an SGLT2 inhibitor approved for type 2 diabetes, heart failure (with reduced or preserved ejection fraction), and chronic kidney disease. NutriStack rates the supporting evidence as strong. Common adult dosing is 5–10 mg once daily (as prescribed by your physician), though a prescriber sets the actual dose. This profile indexes 10 sources.

What it's good for
  • Lowers HbA1c by 0.5–0.8%
  • Heart failure hospitalization reduction (DAPA-HF: 26% RRR)2,3
  • Slows progression of chronic kidney disease (DAPA-CKD)7
  • Weight loss (2–3 kg)
  • Blood pressure reduction
What to watch for
  • Genital mycotic infections
  • Urinary tract infections
  • Polyuria and nocturia
  • Severe renal impairment (eGFR <20 mL/min for diabetes indication; eGFR <25 for HF/CKD)
  • Dialysis

The bottom line

Evidence rating strong. Most-documented uses: lowers hba1c by 0.5–0.8%, heart failure hospitalization reduction (dapa-hf: 26% rrr), slows progression of chronic kidney disease (dapa-ckd). 10 sources indexed (2023–2025), with 0 interaction records on file.

The science

How it works, mechanistically.

Core mechanism

Selectively inhibits SGLT2 in the proximal renal tubule, blocking reabsorption of approximately 50–80 g of glucose per day and causing glycosuria. This insulin-independent mechanism lowers blood glucose while promoting caloric loss, osmotic diuresis, and natriuresis. Additional benefits include reduced intraglomerular pressure, improved tubuloglomerular feedback, and decreased cardiac preload and afterload.

Class
SGLT2 Inhibitor
Dosing

Dosing & protocol.

Common range
5–10 mg once daily (as prescribed by your physician)
Recommended form
Oral tablet

Can be taken with or without food, preferably in the morning.

Safety

Full safety detail.

Side effects

  • Genital mycotic infections
  • Urinary tract infections
  • Polyuria and nocturia
  • Volume depletion and orthostatic hypotension
  • Euglycemic diabetic ketoacidosis (rare)
  • Fournier gangrene (very rare)
  • Back pain

Contraindications

  • Severe renal impairment (eGFR <20 mL/min for diabetes indication; eGFR <25 for HF/CKD)
  • Dialysis
  • Known hypersensitivity to dapagliflozin1,2
  • Type 1 diabetes8
  • Active diabetic ketoacidosis1
Sources

Sources, by evidence tier.

Numbered references. Citations throughout the page link here.

Meta-analyses & systematic reviews

5

Reference material

5
FAQ

Common questions.

Quick answers about Dapagliflozin, drawn from the data on this page.

What is Dapagliflozin?

Dapagliflozin is an SGLT2 inhibitor approved for type 2 diabetes, heart failure (with reduced or preserved ejection fraction), and chronic kidney disease. The DAPA-HF and DAPA-CKD trials established its broad cardiorenal benefits, making it one of the first diabetes medications approved for heart failure independent of diabetes status.

What is Dapagliflozin used for?

Commonly cited benefits of Dapagliflozin include: Lowers HbA1c by 0.5–0.8%; Heart failure hospitalization reduction (DAPA-HF: 26% RRR); Slows progression of chronic kidney disease (DAPA-CKD); Weight loss (2–3 kg); Blood pressure reduction. NutriStack rates the overall evidence as strong.

What is a typical dose of Dapagliflozin?

A typical adult dose of Dapagliflozin is 5–10 mg once daily (as prescribed by your physician). The commonly recommended form is Oral tablet. These are general ranges, not personalized advice; confirm the right dose with a clinician.

What are the side effects of Dapagliflozin?

Reported side effects include genital mycotic infections, urinary tract infections, polyuria and nocturia, volume depletion and orthostatic hypotension, euglycemic diabetic ketoacidosis (rare), fournier gangrene (very rare). This is educational information; check with a healthcare professional before use.

How strong is the evidence for Dapagliflozin?

NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.

Use this with your stack

Dapagliflozin in NutriStack.

Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.

Download on the App Store → Read the methodology

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.